August 13, 2025

Matregenix Secures $2.039 Million Grant for Bone Regeneration Research

News Summary

Matregenix Inc., a nanofiber technology company in Mission Viejo, has received a $2.039 million Phase II grant from the NIDCR to further develop MatriNova™, a nanofiber membrane designed for enhanced bone regeneration. This collaborative project with the University of Michigan School of Dentistry aims to improve guided bone regeneration techniques, reflecting the company’s growing credibility in the healthcare R&D sector. The funding will enable significant advancements in refining MatriNova™, supporting improved patient outcomes in dental and craniofacial procedures.

Mission Viejo, California – Matregenix Inc., a nanofiber technology company based in Mission Viejo, has been awarded a $2.039 million Phase II grant from the National Institute of Dental and Craniofacial Research (NIDCR) to advance the development of MatriNova™, an innovative nanofiber membrane aimed at enhancing bone regeneration. This grant is part of a competitive funding initiative through the National Institutes of Health (NIH).

The grant will specifically support the advancement of MatriNova™, which is designed for use in guided bone regeneration (GBR) procedures. The project is a collaborative effort with the University of Michigan School of Dentistry, directed by Professor Marco Bottino. This partnership builds on an existing relationship established in 2021, illustrating a commitment to harnessing academic expertise in the field of dental and craniofacial surgery.

Matregenix has achieved significant success in securing funding through Small Business Innovation Research (SBIR) awards, reflecting the company’s innovative potential and credibility within the healthcare research and development (R&D) sector. To date, the company has received a total of nine SBIR and Small Business Technology Transfer (STTR) grants from various U.S. federal agencies including the NIH and the Department of Defense.

The NIH Phase II grant will facilitate major advancements in refining and validating the MatriNova GBR membrane, which is designed to enhance bone healing options for patients undergoing dental and craniofacial procedures. As guided bone regeneration plays a crucial role in these medical interventions, the development of more effective materials promises to improve patient outcomes dramatically.

In addition to securing funding, Matregenix has scaled its operations by moving into a state-of-the-art manufacturing facility. This new 18,000 sq. ft. facility, located in Mission Viejo, enhances the company’s capacity for scalable nanofiber production. The upgraded manufacturing capabilities are expected to meet the growing demand for advanced biomaterials and expedite the transition from laboratory innovations to market applications.

Significance of the Grant

The recent grant marks a significant milestone for Matregenix, as it not only supports the development of an innovative product but also validates the company’s technology platform. The funding is instrumental in addressing unmet needs in the biomedical sphere, particularly in improving techniques associated with bone regeneration.

Expanding Opportunities

Matregenix specializes in the design, development, and manufacturing of highly tunable nanofibrous materials tailored for various applications. Their focus spans not only the biomedical sector but also filtration solutions, thus providing comprehensive development and manufacturing services aimed at a broader range of market needs.

Future Prospects

Looking ahead, the innovation presented by MatriNova™ could lead to significant advancements in dental and craniofacial care, potentially transforming how medical professionals approach bone regeneration. With the backing of NIH funding and strategic collaboration with academic institutions, Matregenix is well-positioned to influence the future of biomaterials in healthcare.

The combined efforts of Matregenix and the University of Michigan are set to pave the way for groundbreaking developments that could impact countless patients requiring effective solutions for bone healing. As the company continues to expand its technological and manufacturing capabilities, the future of Matregenix appears promising.